We believe this site might serve you best:

United States

United States

Language: English

Promega's Cookie Policy

Our website uses functional cookies that do not collect any personal information or track your browsing activity. When you select your country, you agree that we can place these functional cookies on your device.

Product Availability Update

Promega Manufacturing and Delivery Systems continue to be fully operational during the COVID-19 outbreak. Our teams are in regular contact with suppliers and distributors worldwide and are taking all steps necessary to address both demands for diagnostic tools and reliable delivery of all products as quickly as possible. Learn more

Our website does not fully support your browser.

We've detected that you are using an older version of Internet Explorer. Your commerce experience may be limited. Please update your browser to Internet Explorer 11 or above.

Citations Search

Sort By:

J. Med. Chem. 61(19), 8504-8535. Emerging Approaches for the Identification of Protein Targets of Small Molecules - A Practitioners’ Perspective. 2018

Comess, K.M., McLoughlin, S.M., Oyer, J.A., Richardson, P.L., Stöckmann, H., Vasudevan, A., and Warder, S.E.

Notes: This review delves into the drug discovery pipeline, focusing on both phenotypic drug discovery (PDD) and target-based drug discovery (TDD) and the importance of experiments which determine the mechanism of action (MOA) of drugs. NanoBRET is highlighted as a highly specific assay for the measurement of target interaction. Specifically, the precise tagging of a target greatly minimizes assay cross-talk. (5122)

Expand Full Notes »

Oncotarget 8(41), 70828-70840. Histone deacetylase inhibitor thailandepsin-A activates Notch signaling and suppresses neuroendocrine cancer cell growth in vivo. 2017

Jang, S. et al.

Notes: Activation of Notch isoforms via histone deacetylase inhibitors (HDACi) has been shown to suppress neuroendocrine (NE) cancers. Here, a novel HDACi called thailandepsin A (TDP-A) was characterized and shown to induce cell cycle arrest and apoptosis. The NanoBRET Target Engagement system was used to determine TDP-A binding to HDAC1. TT cells expressing an HDAC1-NanoLuc fusion were treated with TDP-A and competed HDAC tracer compound to determine in vivo binding affinity.  (5131)

Expand Full Notes »

Anal. Biochem. 489, 1–8. A luminescent assay for real-time measurements of receptor endocytosis in living cells. 2015

Robers, M. B., Binkowski, B. F., Cong, M., Zimprich, C., Corona, C., McDougall, M., Otto, G., Eggers, C. T., Hartnett, J., Machleidt, T., Fan, F. and Wood, K. V.

Notes: The authors describe a new method for real-time analysis of ligand-mediated receptor endocytosis in living cells. They used a BRET-based assay to detect the interactions of ligands with various GPCRs fused to NanoLuc® luciferase. (4693)

Expand Full Notes »

Nature Methods 12(7), 661–663. Application of BRET to monitor ligand binding to GPCRs. 2015

Stoddart, L.A., Johnstone, E.K.M., Wheal, A.J.,  Goulding, J., Robers, M.B., Machleidt, T., Wood, K.V., Hill, S.J., and Pfleger, K.D.G.


Notes: These authors describe a new method for monitoring ligand binding to GPCRs on the surface of living cells. They used NanoLuc luciferase in a BRET-based assay to detect the interactions of ligands with the receptors with an N-terminal NanoLuc fusion. (4589)

Expand Full Notes »

Nat. Commun. 6, 10091 doi:10.1038/ncomms10091. Target engagement and drug residence time can be observed in living cells with BRET. 2015

Robers, M.B, Dart, M.L., Woodroofe, C.C,  Zimprich, C.A., Kirkland, T.A., Machleidt, T., Kupcho, K.R., Levin, S., Hartnett, J.R., Zimmerman, K., Niles, A.L., Ohana, R.F., Daniels, D.L., Slater, M., Wood, M.G., Cong, M., Cheng Y., and Wood, K.V.


Notes: This paper describes a method for using bioluminescence resonance energy transfer (BRET) to reveal the binding characteristics of a drug with selected targets in live cells. The authors used cell-permeable fluorescent tracers in a competitive binding assay to quantify drug engagement with target proteins fused to Nanoluc luciferase. Using this approach, they were able to profile isozyme-specific engagement and binding kinetics for a panel of histone deacetylase (HDAC) inhibitors. (4587)

Expand Full Notes »